These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38224565)

  • 1. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
    Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
    Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
    Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
    Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
    Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of SOS1 Inhibitor-Based Degraders to Target
    Bian Y; Alem D; Beato F; Hogenson TL; Yang X; Jiang K; Cai J; Ma WW; Fernandez-Zapico M; Tan AC; Lawrence NJ; Fleming JB; Yuan Y; Xie H
    J Med Chem; 2022 Dec; 65(24):16432-16450. PubMed ID: 36459180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
    Sudhakar N; Yan L; Qiryaqos F; Engstrom LD; Laguer J; Calinisan A; Hebbert A; Waters L; Moya K; Bowcut V; Vegar L; Ketcham JM; Ivetac A; Smith CR; Lawson JD; Rahbaek L; Clarine J; Nguyen N; Saechao B; Parker C; Elliott AJ; Vanderpool D; He L; Hover LD; Fernandez-Banet J; Coma S; Pachter JA; Hallin J; Marx MA; Briere DM; Christensen JG; Olson P; Haling J; Khare S
    Mol Cancer Ther; 2024 Oct; 23(10):1418-1430. PubMed ID: 38904222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
    Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
    Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Son of Sevenless 1: The pacemaker of KRAS.
    Kessler D; Gerlach D; Kraut N; McConnell DB
    Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
    He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
    Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
    Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
    Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of PROTACS degrading KRAS and SOS1.
    Hamilton G; Eggerstorfer MT; Stickler S
    Oncol Res; 2024; 32(8):1257-1264. PubMed ID: 39055890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.
    Zhou C; Fan Z; Zhou Z; Li Y; Cui R; Liu C; Zhou G; Diao X; Jiang H; Zheng M; Zhang S; Xu T
    J Med Chem; 2022 Mar; 65(5):3923-3942. PubMed ID: 35230841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
    Zhang S; Zhang Y; Chen X; Xu J; Fang H; Li Y; Liu Y; He H
    J Med Chem; 2022 Dec; 65(23):15856-15877. PubMed ID: 36384290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
    Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
    J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling.
    Liu L; Song Z; Fan G; Lou L; Wang Y; Zhang X; Xiong XF
    Bioorg Med Chem; 2023 Oct; 93():117457. PubMed ID: 37688996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
    Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
    Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
    Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
    Hamilton G; Plangger A
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Type-specific Adaptive Signaling Responses to KRAS
    Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
    Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.